Apolipoprotein B/A1 and risk of cardiovascular disease

The Lancet

Volumn 372, Issue 9634, 2008, Pages 185-186

  Lind, Lars ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; FOLLOW UP; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; MASS SCREENING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR;

EID: 47149083145     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61050-8     Document Type: Note

References (12)

1. McQueen M., Hawken S., Wang X., et al., for the INTERHEART Study Investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372 (2008) 224-233
2. Moller C., Zethelius B., Sundstrom J., et al. Impact of follow-up time and re-measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction. J Intern Med 260 (2006) 22-30
3. Walldius G., Jungner I., Holme I., Aastveit A., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
4. Walldius G., Aastveit A., and Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
5. Lind L. Vasodilation in resistance arteries is related to the apolipoprotein B/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 190 (2006) 378-384
6. Wallenfeldt K., Bokemark L., Wikstrand J., et al. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35 (2004) 2248-2252
7. Simes R., Marschner I., Hunt D., et al., on behalf of the LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 (2002) 1162-1169
8. Lind L., Vessby B., and Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 26 (2006) 406-410
9. Lamarche B., Moorjani S., Lupien P., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 94 (1996) 273-278
10. Ridker P., Rifai N., Cook N., Bradwin G., and Buring J. Non-HDL cholesterol, apolipoproteins A-I and b100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
11. Sharrett A., Ballantyne C., Coady S., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104 (2001) 1108-1113
12. Ingelsson E., Schaefer E., Contois J., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007) 776-785